Events › B2B Event
B2B Event
A small, specialized AACR scientific conference focusing on liver cancer pathogenesis and immune therapies, bringing together researchers, clinicians, and biotech professionals.
Exhibitor mix: Small-scale targeted exhibition adjacent to specialized scientific sessions.
Filter this event to your ICP.
Hundreds of exhibitors here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Organizer
American Association for Cancer ResearchNonprofit · Philadelphia, United States · Founded 1907
The first and largest cancer research organization dedicated to accelerating the prevention and cure of cancer.
Why people attend
Attending scientists and researchers (150-400) looking for specialized tools and pre-clinical/clinical services in liver oncology.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
5 speakers at AACR Special Conference: Advances in the Pathogenesis and Immune Therapies of Liver Cancer
Senior Medical Oncologist and Codirector of the Phase I Clinical Trials Program · Princess Margaret Cancer Centre, University Health Network
"Mapping the Molecular Landscape of Head and Neck Cancer to Inform Pantumor Targeting"
Lillian L. Siu, MD, FAACR, has been researching potential new treatments for head and neck cancer and treating patients with this disease for over 30 years. Recently, she has turned her attention to intercepting cancer earlier. She served as President of the AACR.
Also speaking at AACR Drug Discovery and Development (AACR D3) 2026
Baylor College of Medicine
"Targeting Stage 0: Precision-Based Prevention"
Sharon E. Plon, MD, PhD, discussed exciting new opportunities for cancer prevention research in children, including genomic screening for newborns.
Also speaking at AACR Drug Discovery and Development (AACR D3) 2026
David Geffen School of Medicine at the University of California, Los Angeles
"Targeting Stage 0: Precision-Based Prevention"
Joann G. Elmore, MD, MPH, explored the role AI can play in improving early cancer detection and discussed the PRISM trial.
Also speaking at AACR Drug Discovery and Development (AACR D3) 2026
Newcastle University
"Targeting Stage 0: Precision-Based Prevention"
John Burn, MD, discussed the CaPP3 study on aspirin for cancer prevention in Lynch syndrome.
Also speaking at AACR Drug Discovery and Development (AACR D3) 2026
Fred Hutch Cancer Center
"Targeting Stage 0: Precision-Based Prevention"
Mary (Nora) L. Disis, MD, discussed preventive cancer vaccines for Lynch syndrome.
Also speaking at AACR Drug Discovery and Development (AACR D3) 2026
More events in United States
Frequently asked questions